Evidence method
Level · gp.fundamentals.capex_revenue_ratio
5.20% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIK · Jun 30, 2025
Anika Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001171843-25-004826General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-0.67% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-32.69% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
59.97% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
50.90% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-14.81% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
22.37% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
9.03% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History15 statesHistory building
Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 10.79%
- Current
- 5.20%
- Delta
- -5.59%
- Previous
- -0.50%
- Current
- -0.67%
- Delta
- -0.17%
- Previous
- -35.42%
- Current
- -32.69%
- Delta
- 2.74%
- Previous
- 81.53%
- Current
- 59.97%
- Delta
- -21.57%
- Previous
- 56.10%
- Current
- 50.90%
- Delta
- -5.20%
- Previous
- -16.37%
- Current
- -14.81%
- Delta
- 1.56%
- Previous
- 23.15%
- Current
- 22.37%
- Delta
- -0.78%
- Previous
- 10.94%
- Current
- 9.03%
- Delta
- -1.91%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIK Fundamental State →Has State · Anika Therapeutics, Inc. →Transitioned To · ANIK Fundamental State →Transitioned To · ANIK CAPEX_INTENSITY_DECREASED →Transitioned To · ANIK CASH_GENERATION_DECREASED →Transitioned To · ANIK GROWTH_INCREASED →Transitioned To · ANIK INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIK MARGIN_DECREASED →Transitioned To · ANIK PROFITABILITY_INCREASED →Transitioned To · ANIK R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIK SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.